sunitinib jgl 12,5 mg tvrde kapsule
jadran galenski laboratorij d.d., svilno 20, rijeka, hrvatska - сунитиниб - kapsula, tvrda - urbroj: jedna kapsula sadrži 12,5 mg sunitiniba
sunitinib jgl 25 mg tvrde kapsule
jadran galenski laboratorij d.d., svilno 20, rijeka, hrvatska - сунитиниб - kapsula, tvrda - urbroj: jedna kapsula sadrži 25 mg sunitiniba
sunitinib jgl 50 mg tvrde kapsule
jadran galenski laboratorij d.d., svilno 20, rijeka, hrvatska - сунитиниб - kapsula, tvrda - urbroj: jedna kapsula sadrži 50 mg sunitiniba
atrovent n 20 µg/1 doza rastvor za inhaliranje pod pritiskom
boehringer ingelheim bh d.o.o. - ipratropijum bromid - rastvor za inhaliranje pod pritiskom - 20 µg/1 doza - 1 doza rastvora za inhaliranje pod pritiskom sadrži: 20 mcg ipratropijbromida
sunigen 12,5 mg/1 kapsula kapsula, tvrda
viennapharm d.o.o. - sunitinib - kapsula, tvrda - 12,5 mg/1 kapsula - 1 kapsula, tvrda sadrži: 12,5 mg sunitiniba
sunigen 25 mg/1 kapsula kapsula, tvrda
viennapharm d.o.o. - sunitinib - kapsula, tvrda - 25 mg/1 kapsula - 1 kapsula, tvrda sadrži: 25 mg sunitiniba
sunigen 50 mg/1 kapsula kapsula, tvrda
viennapharm d.o.o. - sunitinib - kapsula, tvrda - 50 mg/1 kapsula - 1 kapsula, tvrda sadrži: 50 mg sunitiniba
memalis 20mg film tableta
"goodwill pharma" druŠtvo sa ograniČenom odgovornoŠĆu podgorica - memantin - film tableta - 20mg
memalis 10mg film tableta
"goodwill pharma" druŠtvo sa ograniČenom odgovornoŠĆu podgorica - memantin - film tableta - 10mg
clopidogrel acino
acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotska sredstva - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.